No significant difference in neutrophil activation found among three H2RAs

Digestive and Liver Disease

Volumn 39, Issue 2, 2007, Pages 130-135

  Fukuda, M ^a   Shirasaka, D ^a   Aoyama, N ^a   Miki, I ^a   Kachi, M ^a   Morita, Y ^a   Tamura, T ^a   Kasuga, M ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

H. pylori; Histamine 2 receptor antagonist; Neutrophil activation

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 8; LAFUTIDINE; MYELOPEROXIDASE; RANITIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; LEUKOCYTE ACTIVATION; MALE; NONHUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ADULT; DYSPEPSIA; FAMOTIDINE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; PEROXIDASE; PIPERIDINES; PYRIDINES; RANITIDINE;

EID: 33846276202     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.09.019     Document Type: Article

References (17)

1. Caselli M., Parente F., Palli D., Covacci A., Alvisi V., Gasbarrini G., et al. 'Cervia Working Group Report': guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig Liver Dis 33 (2001) 75-80
2. Vaira U., Gatta L., Ricci C., D'Anna L., and Iglioli M.M. Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 33 (2001) 788-794
3. Talley N.J., and Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 50 (2002) iv36-iv41
4. Kuipers E.J., Uyterlinde A.M., Pena A.S., Hazenberg H.J., Bloemena E., Lindeman J., et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 90 (1995) 1401-1406
5. Logan R.P., Walker M.M., Misiewicz J.J., Gummett P.A., Karim Q.N., and Baron J.H. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36 (1995) 12-16
6. Mikawa K., Akamatsu H., Nishina K., Shiga M., Maekawa N., Obara H., et al. The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Anesth Analg 89 (1999) 218-224
7. Okajima K., Murakami K., Liu W., and Uchiba M. Inhibition of neutrophil activation by ranitidine contributes to prevent stress-induced gastric mucosal injury in rats. Crit Care Med 28 (2000) 2858-2865
8. Harlan J.M. Leukocyte-endothelial interaction. Blood 65 (1985) 513-525
9. Dixon M.F., Genta R.M., Yardley J.H., and Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20 (1996) 1161-1181
10. Matheson N.R., Wong P.S., and Travis J. Isolation and properties of human neutrophil myeloperoxidase. Biochemistry 20 (1981) 325-330
11. Bradley P.P., Priebat D.A., Christensen R.D., and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78 (1982) 206-209
12. Tummuru M.K., Cover T.L., and Blaser M.J. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect Immun 61 (1993) 1799-1809
13. Crabtree J.E., Farmery S.M., Lindley I.J., Figura N., Peichl P., and Tompkins D.S. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 47 (1994) 945-950
14. Okajima K., Harada N., and Uchiba M. Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation. J Pharmacol Exp Ther 301 (2002) 1157-1165
15. Yuki H., Kamato T., Nishida A., Fujihara A., Takeda M., and Miyata K. Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs. Jpn J Pharmacol 63 (1993) 345-351
16. Echizen H., and Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 21 (1991) 178-194
17. Castaneda-Hernandez G., Flores-Murrieta F.J., Granados-Soto V., Herrera-Abarca A., Perez-Urizar J., Herrera J.E., et al. Pharmacokinetics of oral ranitidine in Mexicans. Arch Med Res 27 (1996) 349-352